Biosimilars Bill Offers New Hope

This post on Pharmafocus discusses that the US has gotten a step closer to being able to market generic verions of biologic drugs in the USA for the first time, if the Pathway for Biosimilars Act is passed. Europe has seen a similar legislation pass in 2003, but now the Obama administration seems determined to bring biosimilars here in the US to reduce on healthcare costs. There is much skepticism though as many people say that biosimilars do not behave the same way as originator drugs when it comes to safety and efficacy. What is your take?

If you’re interested in connecting with other professionals in the Biosimilars field, join us at LinkedIn.

Share this article with your social network, just click below to share now!

Share |